Biovica wins ~$85K DiviTum TKa Phase 1 testing work order
Biovica received its first work order under a new Master Services Agreement valued at about $85K to perform DiviTum TKa testing for a First-in-Human Phase 1 study of an oral next-generation CDK inhibitor at its lab in Sweden.
Biovica has received its first work order under a new Master Services Agreement, worth approximately $85K, to conduct DiviTum TKa testing in a First-in-Human Phase 1 study of an oral next-generation CDK inhibitor. Testing will be carried out at Biovica’s lab in Sweden.